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Abstract 
Bioreactor systems will likely play a key role in establishing regulatory compliant and cost-
effective production systems for manufacturing engineered tissue grafts for clinical 
applications. However, the automation of bioreactor systems could become considerably more 
complex and costly due to the requirements for additional storage and liquid handling 
technologies if unstable supplements are added to the culture medium. Ascorbic acid (AA) is 
a bioactive supplement that is commonly presumed to be essential for the generation of 
engineered cartilage tissues. However, AA can be rapidly oxidized and degraded. In this 
work, we addressed whether human nasal chondrocytes can re-differentiate, undergo 
chondrogenesis, and generate a cartilaginous extracellular matrix when cultured in the 
absence of AA. We found that when chondrocytes were cultured in 3D micromass pellets 
either with or without AA, there were no significant differences in their chondrogenic 
capacity in terms of gene expression or the amount of glycosaminoglycans. Moreover, 3D 
pellets cultured without AA contained abundant collagen type II and collagen type I 
extracellular matrix. While the amounts of collagen II and I were significantly lower (34% 
and 50% lower) than in pellets cultured with AA, collagen fibers had similar thicknesses and 
distributions for both groups, as shown by SEM imaging. Despite the reduced amounts of 
collagen, if engineered cartilage grafts can be generated with sufficient properties that meet 
defined quality criteria without the use of unstable supplements such as AA, bioreactor 
automation requirements can be greatly simplified, thereby facilitating the development of 
more compact, user-friendly, and cost-effective bioreactor-based manufacturing systems.  
 
Keywords: ascorbic acid, collagen, tissue engineering, cartilage, hydroxyproline, nasal 
chondrocytes 
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1. Introduction 
While engineered tissue grafts hold immense therapeutic potential, a number of obstacles 
currently exist that inhibit the translation of scientific innovation into commercially viable 
therapies. Among the obstacles that must be addressed are crucial challenges associated with 
the manufacturing of engineered grafts (Lysaght et al., 2008, Martin et al., 2014). Bioreactor 
systems, which automate and standardize bioprocesses, have the potential to overcome key 
manufacturing challenges and facilitate regulatory compliant and cost-effective production of 
engineered tissue grafts (Martin et al., 2009, Ratcliffe and Niklason 2002). 
 
The automation of bioreactor systems, however, can become considerably complex due to the 
complicated liquid handling and storage conditions imposed by unstable compounds used in 
many culture medium formulations. We have previously found the growth factor TGF-β to 
maintain high bioactivity even when stored at 37°C for up to three weeks (Vonwil et al., 
2008), however, the stability of other medium supplements should also be assessed. Ascorbic 
acid (AA) is a bioactive supplement typically used in the generation of engineered cartilage, 
which can be rapidly oxidized to dehydroascorbic acid and further degraded by oxidation or 
hydrolysis, resulting in short-time stability (Chepda et al., 2001, Fisher and Naughton 2004, 
Kurano et al., 1990). Several AA derivatives have been developed with protective groups 
against degradation, such as the more stable but equally bioactive ascorbic acid-2-phosphate 
(AA2P) (Takamizawa et al., 2004). Despite its increased stability, AA2P is typically added 
from frozen aliquots at every medium exchange, which drastically complicates bioprocess 
automation due to the additional need for freezing/thawing modules and the associated liquid 
handling technology, therefore presenting significant obstacles towards establishing a i) 
compact, ii) user-friendly, and iii) cost-effective bioreactor-based manufacturing system. 
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In addition to being a notable antioxidant, AA is thought to induce chondrogenesis via an 
upregulation of collagen expression, and is therefore added in most protocols for 
chondrogenic differentiation (Altaf et al., 2006, Cigan et al., 2013, Ibold et al., 2009); an 
essential process in the production of engineered cartilage grafts. Moreover, AA is involved in 
the synthesis of collagens, including collagen type II, a key protein in articular hyaline 
cartilage (Buckwalter and Mankin 1998). In particular, AA serves as a co-factor for the 
enzymes prolyl hydroxylase and lysyl hydroxlase, which are responsible for the hydroxylation 
of proline and lysine residues of the collagen propeptide. This hydroxylation is essential for 
the collagen monomer cross-linking and collagen triple helix stability (Barnes and Kodicek 
1972, Englard and Seifter 1986, Kavitha and Thampan 2008).  
 
Nevertheless, it has been shown in a number of model systems that alternative biomolecules 
are available which could replace AA as an antioxidant and cofactor (e.g., glutathione) 
(Barnes and Kodicek 1972, Englard and Seifter 1986, Flashman et al., 2010, Martensson et 
al., 1993, Nytko et al., 2011), and thus AA may not be required for the generation of hyaline 
cartilage tissues.  
 
In this work, we addressed whether expanded human nasal chondrocytes can re-differentiate, 
undergo chondrogenesis, and generate a cartilagenous extracellular matrix when cultured in 
vitro in the absence of AA. With an increased understanding of the effects of AA on cartilage 
tissue engineering, efficient supplementation regimes can be established to define automation 
requirements, while ensuring graft quality.  
 
2. Materials and Methods 
2.1 Cell isolation and expansion 
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Samples of human cartilage were collected from the nasal septum of 10 patients undergoing 
rhinoplasty (mean age 37 years, range 21–63 years), after informed consent and in accordance 
with the local ethical commission (EKBB; Ref.# 78/07). Cartilage biopsies were digested 
using 0.15% collagenase II (Worthington, UK) for 22 hours at 37°C as previously described 
(Jakob et al., 2003). After digestion, cells were plated in tissue culture flasks at a density of 
1x104 cells/cm2 and cultured in medium consisting of Dulbecco's Modified Eagle's Medium 
containing 4.5mg/ml D-glucose and 0.1mM nonessential amino acids (DMEM, Gibco, Life 
Technologies, Switzerland), 10% fetal bovine serum (FBS), 1mM sodium pyruvate, 100mM 
HEPES buffer, 100U/ml penicillin, 100µg/ml streptomycin, and 0.29mg/ml L-glutamine (all 
from Gibco), supplemented with 1ng/ml transforming growth factor beta-1 (TGF-β1) and 
5ng/ml fibroblast growth factor-2 (FGF-2) (both from R&D Systems, UK) at 37°C and 5% 
CO2 in a humidified incubator (Thermo Scientific Heraeus, USA) (Jakob et al., 2001). When 
approaching 80% confluence, cells were detached using 0.05% trypsin-EDTA (Gibco), re-
suspended in FBS containing 10% dimethyl sulfoxide, transferred to cryovials (Sarstedt, 
Germany) and stored in liquid nitrogen tanks until further use. 
 
2.2 Chondrogenic re-differentiation 
Chondrocytes from frozen aliquots were expanded until passage 2 and re-differentiated by 
culturing as 3D micromass pellets, which were formed by centrifuging 5E+05 cells at 300xg 
in 1.5ml conical tubes (Sarstedt). 3D micromass pellets were cultured for two weeks either 
with or without 100µM ascorbic acid 2-phosphate (Sigma) (experimental groups: +AA2P 
or -AA2P, respectively) in chondrogenic serum-free medium consisting of DMEM containing 
1mM sodium pyruvate, 100mM HEPES buffer, 100U/ml penicillin, 100µg/ml streptomycin, 
0.29g/ml L-glutamine, 1.25mg/ml human serum albumin (CSL Behring, Switzerland), and 
100nM dexamethasone (Sigma, Switzerland), supplemented with 10ng/ml TGF-β1, ITS+1 
(10µg/ml insulin, 5.5µg/ml transferrin, 5ng/ml selenium; Gibco), 0.5mg/ml bovine serum 
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albumin (Sigma), and 4.7µg/ml linoleic acid (Sigma). For an additional experimental group, 
micromass pellets were cultured with AA2P, and the concentration of AA2P remaining in the 
culture medium was readjusted to the initial level of 100µM each day (experimental group: 
Daily AA2P), based on measurements of AA2P (see Section 2.3). As negative controls for 
chondrogenic re-differentiation, one group of micromass pellets was cultured for two weeks 
without AA2P and without ITS+1 (experimental group: -AA2P -ITS). For all experimental 
groups, micromass pellet culture medium was changed twice weekly. 
 
2.3 Ascorbic acid measurements 
AA2P was quantified in chondrogenic medium (both in serum-free medium and in 10% FBS 
containing medium), which was stored at 4°C or 37°C for up to 14 days (0, 1, 2, 4, 7, 10, and 
14 days) using the ferric reducing ascorbate assay kit (FRASC; BioVision, Switzerland), 
according to the manufacturer’s instructions with an additional step in order to measure the 
2-phosphate form. In addition, AA2P was also quantified in the spent medium of +AA2P 
micromass pellet cultures at 0, 1, 2, and 3 days. Briefly, to transform AA2P into measurable 
AA, samples were first incubated with 1unit/100µl of alkaline phosphatase (Sigma, 
Switzerland) for 10min at 37°C. This step was omitted when measuring the medium 
concentration of AA without the 2-phosphate group. Ascorbate oxidase or water was then 
added to generate the AA depleted background or the total oxidant group, respectively. After 
addition of the ascorbic acid reaction mix, absorbance at 593nm was measured and the 
concentration of AA2P or AA was calculated from the difference of the total oxidant and the 
AA depleted group based on an AA standard curve. 
 
2.4 Histology and immunohistochemistry 
Micromass pellets were fixed overnight in 4% formalin and embedded in paraffin. Sections 
5µm in thickness were stained with Safranin-O for glycosaminoglycans (GAG) and 
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hematoxylin as a nuclear counterstaining. Immunohistochemistry against collagen type I 
(No.0863170, MPBiomedicals, France) and collagen type II (No.0863171, MPBiomedicals) 
was performed using the Vectastain ABC kit (Vector Labs, USA) with haematoxylin 
counterstaining as previously described (Scotti et al., 2010). Terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) with an Alexa Fluor 647 dye (Click-iT TUNEL 
assay; Molecular Probes, Switzerland) was performed on formalin-fixed paraffin-embedded 
sections, according to the manufacturer’s instructions. A positive control with DNA strand 
breaks was generated by 30min incubation at room temperature with 1 unit of DNase I 
(Molecular Probes). Immunofluorescence staining against collagen type II was performed on 
OCT (CellPath, UK) embedded 10µm thick cryosections using the collagen type II primary 
antibody (MPBiomedicals, France) and a goat anti-mouse Alexa Fluor 546 secondary 
antibody (Invitrogen), with DAPI as a nuclear counterstain.  
 
2.5 Quantitative RT-PCR 
mRNA of chondrocytes was extracted using Quick-RNA Miniprep (Zymo Research, USA), 
according to the manufacturer’s protocol. DNaseI (Zymo Research) was used to remove trace 
DNA. Isolated RNA was quantified using a NanoDrop spectrophotometer (ThermoFischer 
Scientific). Reverse transcription into cDNA was done from 3µg of RNA by using 500µg/ml 
random hexamers (Promega, Switzerland) and 0.5µl of 200UI/ml SuperScript III reverse 
transcriptase (Invitrogen), in the presence of dNTPs. Real-time PCR was carried out on an 
ABI Prism 7700 Sequence Detection System (Perkin-Elmer/Applied Biosystems, 
Switzerland). After initial denaturation at 95°C for 10min, cDNA was amplified for 40 cycles, 
each consisting of a denaturation step at 95°C for 15sec and an annealing/extension step at 
60°C for 60sec. Primers and probes for aggrecan, versican, collagen type I, collagen type II 
and GAPDH were used with TaqMan Gene Expression Master Mix (Applied Biosystems) as 
previously described (Martin et al., 2001). Assay on-Demand (Applied Biosystems) was used 
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to measure the expression of SOX9 (Hs00165814_m1). The threshold cycle (Ct) value of the 
reference gene GAPDH was subtracted from the Ct value of the gene of interest to derive 
ΔCt. The relative gene expression of each group normalized to the cells after expansion was 
calculated as 2-ΔΔCt. Each sample was assessed at least in duplicate for each gene of interest. 
 
2.6 Biochemical analyses 
Micromass pellets were digested in proteinase K (1mg/ml proteinase K in 50mM Tris with 
1mM EDTA, 1mM iodoacetamide, and 10mg/ml pepstatin A) for 16h at 56°C. The sulphated 
glycosaminoglycan (sGAG) content of pellets was determined by spectrophotometry using 
dimethylmethylene blue, with chondroitin sulphate as a standard (Barbosa et al., 2003). The 
DNA content of pellets was measured using the CyQuant cell proliferation assay kit 
(Invitrogen), with calf thymus DNA as a standard. The amount of sGAG in pellets was then 
normalized to the DNA content. For hydroxyproline quantification, samples were processed 
as previously described (Cigan et al., 2013, Hofman et al., 2011). Briefly, proteinase K 
digested samples were mixed with equal amounts of 12M HCl and hydrolysed at 120°C for 
24h. Specimens were then transferred into 96-well plates and left to dry before addition of 
acetate-citrate buffered chloramine T and incubation for 20min at room temperature. 
Dimethylaminobenzaldehyde was added and the plates heated for 20min to 60°C. Absorbance 
was then measured at 550nm. Concentrations were calculated based on a hydroxyproline 
(Sigma) standard curve. 
 
2.7 Collagen quantification 
Pellets were solubilized by an initial digestion in 25µl of 2mg/ml TPCK-treated bovine 
pancreatic trypsin (in 50mM Tris HCl pH 7.5, 1mM EDTA, 1mM iodoacatamide, 20µg/ml 
Pepstatin A), for 15h at 37 °C. A further 25µl of freshly prepared trypsin solution was added, 
and digests were incubated for 2h at 65°C, with intermittent vortexing. Digests were then 
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boiled for 15min to destroy remaining enzyme activity. The quantity of collagen type II was 
determined using an inhibition ELISA with a mouse IgG monoclonal antibody to denatured 
collagen type II (Dickinson et al., 2005). Collagen type I was measured by inhibition ELISA 
using a rabbit anti-peptide antibody to collagen type I (Hollander et al., 1994). 
 
2.8 Scanning electron microscopy 
For scanning electron microscopy (SEM), pellets were fixed for 2 days in 0.1M cacodylate-
buffered 2% glutaraldehyde at pH 7.2 at 25°C, then glued onto a Teflon disc with a rapidly 
curing epoxy glue (Araldite; Huntsman, UK). Next, the specimens were placed in a cryostat 
microtome to trim off approximately 150µm of the outermost cartilage layer parallel to the 
support surface to assess the central region of the samples. Proteoglycans were then extracted 
in 100mM Soerensen's phosphate buffer (pH 7.2) containing 1mg/ml bovine hyaluronidase 
(type I, Sigma), 1mg/ml trypsin (type I, Sigma) and 0.01% NaN3 at 37°C for 3 days. After 
dehydration in graded ethanol series and critical point drying, samples were sputter-coated 
with 3–5 nm platinum and examined by SEM (Hitachi S-4800 FEG, Japan), operated at 1.5–
5kV accelerating voltage in immersion mode (Stolz et al., 2009, Strobel et al., 2010). The 
collagen fibers within micromass pellets were assessed qualitatively based on the acquired 
SEM images. 
 
2.9 Statistical analysis 
Data are presented as mean and standard deviation of independent experiments with cells 
from at least 2 different donors. For each analysis at least 3 replicate micromass pellets were 
used per condition. Statistical analysis was performed using RStudio version 1.1.149 
(RStudio, Boston, MA; http://www.rstudio.com). The effects of the ascorbic acid treatment 
groups were assessed using a linear mixed effect model. Treatment group was defined as the 
fixed effect and cell donor defined as the random effect. Measurement values were log10 
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transformed and then fit with the mixed effect model using the R package lme4. Differences 
were assessed using a one-way ANOVA followed by a post-hoc Tukey test using the R 
package multcomp. Differences between groups were considered statistically significant for 
p<0.05. 
 
3. Results 
3.1 AA2P concentration in culture media 
In order to test the availability of AA in chondrogenic medium formulations, AA stability was 
determined in stored medium and spent pellet culture medium, with or without FBS, for the 
two week culture period required for automated bioreactor-engineered cartilage (Tonnarelli et 
al., 2016). When media was supplemented with AA, which lacks the protective 2-phosphate 
group, levels were below the detection limit in both stored and spent pellet culture medium at 
all time points, indicating a rapid degradation and/or consumption of this medium supplement 
(data not shown). For the remainder of the study, we therefore exclusively tested media 
supplemented with AA2P, and not AA. In medium containing serum, AA2P was rapidly 
degraded. AA2P was particularly unstable when stored in medium containing serum at 37°C, 
dropping to less than 10% of the initial concentration within 24 hours (Fig. 1a). In serum-free 
culture medium, the concentration of AA2P remained constant for 2 weeks of storage, both at 
4°C and 37°C. However, when culturing micromass pellets in serum-free culture medium, the 
concentration of AA2P decreased by almost 50% within the first 24 hours of culture, and 
further declined to less than 25% of the initial concentration by day 3 (Fig. 1b).  Since a 
constant concentration of AA or AA2P was not maintained in the presence of cultured 
chondrocytes without repeated supplementation (which would ultimately impose critical 
manufacturing challenges when using a closed bioreactor system), we investigated whether 
the continual presence of AA2P was necessary to maintain a chondrogenic phenotype and for 
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the production of components required for engineered cartilage. This question was addressed 
by using nasal chondrocyte pellet cultures in serum-free medium. 
 
3.2 Cell viability 
Since AA is a potent antioxidant that prevents oxidative stress in cells, the effect of its 
absence on cell viability was tested in micromass pellet cultures under normoxic conditions. 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was similar in 
pellets cultured with (+AA2P and Daily AA2P) or without AA2P (-AA2P), with only a few 
instances of DNA fragmentation detected among all conditions with ITS (Fig. 2a); whereas in 
the absence of both AA2P and ITS (-AA2P -ITS) all cells exhibited oxidative stress. In 
addition, the DNA content of all pellets cultured with ITS was the same irrespective of AA2P 
supplementation, indicating that cell number was unaffected (Fig. 2b). 
 
3.3 Gene expression and glycosaminoglycan deposition 
No significant differences were found in the expression of genes associated with either 
chondrogenic differentiation (collagen type II, aggrecan and sox-9) or chondrocyte 
dedifferentiation (collagen type I and versican) irrespective of AA2P supplementation (Fig. 
3a). Safranin-O staining of micromass pellets showed similar cell densities and uniform GAG 
deposition irrespective of the AA2P supplementation (Fig. 3b). Negative control -AA2P -ITS 
pellets were filled with extracellular matrix that was negative for GAG staining. Biochemical 
quantification of pellets showed that the sGAG/DNA content was consistent with histological 
assessment and unaffected by AA2P supplementation. In contrast, -AA2P -ITS pellets had 
significantly lower sGAG/DNA (Fig. 3c). 
 
3.4 Collagen extracellular matrix 
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Since ascorbic acid is a cofactor in the hydroxylation of proline during collagen synthesis, we 
tested the effects of AA2P on collagen deposition and hydroxylation. Immunohistochemical 
analysis showed that micromass pellets stained positive for both collagen type II and collagen 
type I, with intensities and staining patterns unaffected by AA2P supplementation (Fig. 4). 
Collagen type I was distributed mainly on the edge of the pellets, while collagen type II was 
abundantly present throughout the whole pellet, except for a thin outer rim, indicating 
deposition of a cartilage like matrix. Removal of ITS resulted in no positive collagen type II 
or I staining.  
 
Quantification of pellet collagen type II and collagen type I by specific immunoassays 
confirmed deposition of both proteins even in the absence of AA2P. The amount of collagen 
type II and collagen type I in -AA2P pellets were 34% less (p<0.01) and 50% less (p<0.001) 
than in +AA2P pellets, respectively (Fig 5a and 5b). The amount of collagens in the Daily 
AA2P pellet group were similar and not significantly different from the +AA2P group. In 
contrast, -AA2P -ITS pellets contained significantly less collagen type II and virtually no 
collagen type I. Post-translational hydroxylation of collagens was confirmed by the 
quantification of the hydroxyproline/collagen content in pellets, which was similar for all 
experimental conditions, irrespective of the AA2P condition (Fig. 5c). In contrast, the 
hydroxyproline/collagen content was significantly lower in negative control pellets 
(-AA2P -ITS). 
 
3.5 Collagen secretion 
Since removal of AA2P could affect deposition of collagen within the extracellular matrix due 
to impaired collagen secretion, we used high magnification immunofluorescence to assess 
intracellular and extracellular collagen type II accumulation. As seen in Figure 6, collagen 
type II was evenly distributed in the extracellular matrix, but no intracellular retention of 
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vesicle-like structures staining positive for collagen type II could be observed, independent of 
the AA2P condition. No extracellular or intracellular collagen type II was detected in the 
negative control pellets (-AA2P -ITS). 
 
3.6 Collagen fibril network 
We investigated whether the absence of AA2P had an effect on the collagen fibrils deposited 
within the micromass pellets. As seen in Figure 6, SEM imaging of micromass pellets showed 
dense networks of collagen fibrils, which appeared to have similar thicknesses and 
distributions for all AA2P conditions. In contrast, no collagen fibrils could be observed in the 
negative control pellets (-AA2P -ITS). 
 
4. Discussion 
In this work, we have shown that AA2P was rapidly degraded in medium used for culture of 
engineered cartilage tissues. However, when chondrocytes were cultured in 3D micromass 
pellets either with or without AA2P, we found no significant differences in their chondrogenic 
capacity in terms of gene expression and sGAG deposition. Interestingly, pellets cultured 
without AA2P contained abundant collagen type II and collagen type I extracellular matrix. 
While the amount of these collagens was significantly lower in -AA2P pellets than those 
cultured with AA2P, the network of collagen fibers appeared quite similar. 
 
AA is known to be an unstable component of cell culture medium due to a fast degradation 
process catalyzed by iron and copper ions (Fisher and Naughton 2004). AA2P, with the 
protective phosphate group, has been shown to be more stable (Takamizawa et al., 2004), 
however the stability can be affected by specific components of the culture medium. We have 
demonstrated that AA2P was stable in serum-free medium for up to two weeks when stored at 
either 4°C or 37°C. That stability was drastically reduced in medium containing serum, likely 
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due to the presence of phosphatases in the serum (Chepda et al., 2001). When culturing 
chondrocytes in micromass pellets, the AA2P concentration was reduced by half after 24 
hours, even in serum-free medium. It is likely that membrane-bound or secreted phosphatases 
degraded AA2P to AA, which was then either rapidly degraded or taken up by the cells 
(Takamizawa et al., 2004). To account for the depletion of AA2P during culture, in 
subsequent experiments we included an experimental group in which the level of AA2P was 
measured and adjusted daily to the initial concentration (i.e., 100µM) in order to assess the 
effects of a more constant level of AA2P in the culture medium. While the number of cells 
would likely have an impact on the level of AA2P depletion throughout culture, the ratio of 
cell number to culture medium volume (1E+06 cells/ml) used in this study has clinical 
relevance, since it is the same ratio used in the manufacturing of cartilage grafts for clinical 
studies (Mumme et al., 2016). 
 
Following two weeks of micromass pellet culture under normoxia, we observed no 
differences in apoptosis, necrosis, or DNA content, regardless of the AA2P supplementation 
regime. Endogenous antioxidants such as glutathione have likely compensated for the absence 
of AA2P and provided sufficient protection against reactive oxygen and nitrogen species 
(Espinosa-Diez et al., 2015).  
 
We compared de-differentiated monolayer expanded chondrocytes with re-differentiated 
chondrocytes in micromass pellets and found an upregulation of genes associated with 
chondrogenic differentiation (collagen type II and aggrecan) in pellets. Interestingly, the 
expression of all genes assessed, whether chondrogenic or not, was similar for pellets cultured 
with or without AA2P. Biochemical and histological assessments also indicated no 
differences between +AA2P, Daily AA2P, or -AA2P pellets. In the presence of ITS, with or 
without AA2P, chondrocytes were rounded and embedded within lacunae, and surrounded by 
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dense GAG matrix; indicating that the chondrogenic capacity of human nasal chondrocytes 
was not significantly affected by AA2P.  
 
Immunohistochemical and ELISA assays confirmed that chondrocytes could produce collagen 
type II and collagen type I proteins in the absence of AA2P, although to lesser extent than 
when cultured with AA2P. Quantification of collagens type II and I by ELISA enabled 
collagen to be determined independent of hydroxyproline quantification (Dickinson et al., 
2005, Hollander et al., 1994), thus enabling the proportion of hydroxyproline in collagens to 
be calculated. This calculation was based on the assumption that the majority of collagen in 
pellets was type II and I, however it is possible that other collagens (e.g., type III and XII) 
were also present in small amounts (Taylor et al., 2015). Additional biochemical analysis 
indicated that the amount of hydroxyproline/collagen was similar for +AA2P, Daily 
AA2P, -AA2P, suggesting that the enzyme proline hydroxylase was functional even in the 
absence of AA2P. These findings are consistent with previous studies demonstrating that AA 
was not essential as a co-factor for prolyl hydroxylase under certain conditions. In fact, 
mutant mice lacking the final enzyme for AA synthesis were shown to have normal collagen 
production, and the absence of AA had no direct effect on collagen hydroxylation in guinea 
pigs (Dickinson et al., 2005, Parsons et al., 2006, Peterkofsky 1991). Other molecules present 
in the medium such as glutathione or cysteine may have compensated for the lack of a co-
factor, even if at a lower activity (Barnes and Kodicek 1972). Indeed, lysyl hydroxylase can 
function in the absence of AA for a short period (Puistola et al., 1980). Alternatively AA 
could be recycled over long durations, which could also explain why collagen production 
without ascorbic acid supplementation has been observed in vivo (McNulty et al., 2005, 
Qutob et al., 1998). Interestingly, no increase in collagen deposition (Fig. 4) or  
hydroxylation/collagen ratio (Fig. 5) was observed when maintaining the concentration of 
AA2P on a daily basis close to initial levels (Daily AA2P); despite the observed reduction in 
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available AA after 24 h of pellet culture (Fig 1b). This indicates that the applied regime of 
twice weekly medium exchanges, was sufficient to reach saturation of AA-dependent 
mechanisms, before available AA was completely diminished. 
 
Despite similar gene expression, reduced amounts of collagen type II and collagen type I 
in -AA2P pellets could have resulted from inhibited collagen secretion (Bentovim et al., 
2012). Based on immunofluorescence staining for collagen type II, no intracellular retention 
of vessel-like structures could be detected (Gelse et al., 2008), suggesting collagen secretion 
may not have been significantly impaired in the absence of AA2P. However, additional 
analyses should be performed in order to more closely investigate potential impaired collagen 
secretion, such as TEM imaging or an investigation of the unfolded protein response (UPR). 
 
The unique biomechanical features of articular cartilage largely depend on its highly 
organized molecular and structural composition (Buckwalter and Mankin 1998). Based on 
SEM imaging, all micromass pellets qualitatively appeared to have similar fiber thicknesses 
and distributions, regardless of AA2P supplementation. Together with the similar 
hydroxylation profiles, this suggests that the extracellular matrix engineered with or without 
AA2P could potentially have similar biomechanical properties (Berg and Prockop 1973). This 
hypothesis remains to be investigated in future studies. Furthermore, the analysis of collagen 
crosslinks would provide insight into the integrity of collagen fibrils in the absence of AA2P, 
since crosslink formation requires hydroxylation of lysine residues, and hydroxylysine 
derived immature crosslinks such as lysinonorleucine provide tensile strength to collagen 
fibrils (Davison 1989). Maturation of collagen crosslinks into tri and tetravalent hydroxyl-
pyridinoline crosslinks increases collagen fibril strength further (Reiser et al., 1987), but this 
condensation reaction is unlikely to occur within two weeks of collagen synthesis (Murdoch 
et al., 2016).  
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In this work, we have shown that de-differentiated human nasal chondrocytes cultured as 
micromass pellets without AA2P, could re-differentiate and generate cartilaginous tissue. The 
engineered tissues had similar properties to those generated in the presence of AA2P, with the 
exception of lower collagen content. Although the amount of collagen type II was reduced by 
34% in the absence of ascorbic acid, the question remains whether this slight reduction in 
collagen content would have any clinical impact. Clinical studies aimed at understanding the 
effect of the maturation stage of engineered cartilage tissues on cartilage repair will help to 
address the lingering question in cartilage tissue engineering “how good is good enough?”. If 
engineered cartilage grafts can be generated with sufficient properties to meet defined quality 
criteria without the use of unstable medium components such as ascorbic acid, bioreactor 
automation requirements can be greatly simplified, thereby facilitating the development of a 
more compact, user-friendly, and cost-effective bioreactor-based manufacturing system. 
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Figure Legends 
Figure 1. Availability of AA2P in stored medium and in micromass pellet cultures. (a) 
Concentration of AA2P in serum-free medium (SF) or 10% fetal bovine serum-containing 
medium (CM) stored at 4°C or 37°C for up to 14 days. (b) Concentration of AA2P in spent 
serum-free medium of micromass pellet cultures. 
Figure 2. (a) TUNEL staining (red) and DAPI nuclear counterstaining (blue) of micromass 
pellets after 2 weeks of chondrogenic culture. Arrows point to TUNEL positive staining. 
(Scale bar 50µm). (b) DNA quantification of micromass pellets. Data are presented as mean ± 
standard deviation. 
Figure 3. Gene expression and glycosaminoglycan content following two weeks of 
micromass pellet culture. (a) The expression of genes associated with differentiated (collagen 
type II, sox-9, aggrecan) and de-differentiated chondrocytes (collagen type I, versican) after 2 
weeks of chondrogenic differentiation. (b) Safranin-O staining of histological sections of 
micromass pellets. (Scale bar indicates 200µm.) (c) sGAG/DNA of micromass pellets 
normalized to +AA2P values of the same donor. Data are presented as mean ± standard 
deviation. (*indicates statistically significant differences from other groups with p<0.05) 
Figure 4. Collagen type II and collagen type I immunohistochemistry of micromass pellets 
after two weeks of culture. (Scale bar indicates 200µm.) 
Figure 5. Quantification of (a) collagen type II, (b) collagen type I, and (c) the ratio of 
hydroxyproline to collagen, following two weeks of micromass pellet culture. Values were 
normalized to the respective value of +AA2P of the same donor. Data are presented as mean ± 
standard deviation.  (*indicates statistically significant difference from +AA2P with p<0.05)  
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Figure 6. (a) Cryosections of micromass pellets stained by immunofluorescence against 
collagen type II (red) and DAPI nuclear counterstain (blue). (Scale bar indicates 10µm.) (b) 
Scanning electron microscopy of micromass pellets showing the network of collagen fibrils. 
(Scale bar indicates 300nm) 
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